Switch theme
Sign up to access all valuation multiples
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
2003
286
LTM Revenue $81.5M
LTM EBITDA -$132M
$558M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zymeworks has a last 12-month revenue of $81.5M and a last 12-month EBITDA of -$132M.
In the most recent fiscal year, Zymeworks achieved revenue of $76.3M and an EBITDA of -$109M.
Zymeworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zymeworks valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $76.0M | $76.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$121M | -$109M | XXX | XXX | XXX |
| EBITDA Margin | -159% | -142% | XXX | XXX | XXX |
| Net Profit | $124M | -$119M | XXX | XXX | XXX |
| Net Margin | 164% | -156% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zymeworks's stock price is $11.
Zymeworks has current market cap of $765M, and EV of $558M.
See Zymeworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $558M | $765M | XXX | XXX | XXX | XXX | $-1.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zymeworks has market cap of $765M and EV of $558M.
Zymeworks's trades at 6.8x LTM EV/Revenue multiple, and -4.2x LTM EBITDA.
Analysts estimate Zymeworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zymeworks and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $558M | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | -5.1x | XXX | XXX | XXX |
| P/E | -6.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZymeworks's NTM/LTM revenue growth is 41%
Zymeworks's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Zymeworks's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zymeworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zymeworks and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -142% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -101% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 81% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 176% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 257% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zymeworks acquired XXX companies to date.
Last acquisition by Zymeworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Zymeworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zymeworks founded? | Zymeworks was founded in 2003. |
| Where is Zymeworks headquartered? | Zymeworks is headquartered in United States of America. |
| How many employees does Zymeworks have? | As of today, Zymeworks has 286 employees. |
| Who is the CEO of Zymeworks? | Zymeworks's CEO is Mr. Kenneth Galbraith. |
| Is Zymeworks publicy listed? | Yes, Zymeworks is a public company listed on NAS. |
| What is the stock symbol of Zymeworks? | Zymeworks trades under ZYME ticker. |
| When did Zymeworks go public? | Zymeworks went public in 2017. |
| Who are competitors of Zymeworks? | Similar companies to Zymeworks include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zymeworks? | Zymeworks's current market cap is $765M |
| What is the current revenue of Zymeworks? | Zymeworks's last 12-month revenue is $81.5M. |
| What is the current EBITDA of Zymeworks? | Zymeworks's last 12-month EBITDA is -$132M. |
| What is the current EV/Revenue multiple of Zymeworks? | Current revenue multiple of Zymeworks is 6.8x. |
| What is the current EV/EBITDA multiple of Zymeworks? | Current EBITDA multiple of Zymeworks is -4.2x. |
| What is the current revenue growth of Zymeworks? | Zymeworks revenue growth between 2023 and 2024 was 0%. |
| Is Zymeworks profitable? | Yes, Zymeworks is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
